| Identification | Back Directory | [Name]
MIN-101 | [CAS]
359625-79-9 | [Synonyms]
MT210
MT-210
MT 210
MIN-101
CYR-101
Roluperidone
CYR-101(Roluperidone)
Roluperidone (CYR-101)
MIN-101; MIN 101; MIN101; CYR-101; CYR 101; CYR101; MT-210; MT 210; MT210;
1H-Isoindol-1-one, 2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]-4-piperidinyl]methyl]-2,3-dihydro- | [Molecular Formula]
C22H23FN2O2 | [MDL Number]
MFCD28502826 | [MOL File]
359625-79-9.mol | [Molecular Weight]
366.429 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:33.33(Max Conc. mg/mL);90.96(Max Conc. mM) | [form ]
A solid | [color ]
White to yellow | [InChI]
InChI=1S/C22H23FN2O2/c23-19-7-5-17(6-8-19)21(26)15-24-11-9-16(10-12-24)13-25-14-18-3-1-2-4-20(18)22(25)27/h1-8,16H,9-15H2 | [InChIKey]
RNRYULFRLCBRQS-UHFFFAOYSA-N | [SMILES]
C1(=O)C2=C(C=CC=C2)CN1CC1CCN(CC(C2=CC=C(F)C=C2)=O)CC1 |
| Hazard Information | Back Directory | [Uses]
Roluperidone (CYR-101) is a novel cyclic amide derivative that has high equipotent affinities for 5-HT2A and sigma-2 receptors (Ki of 7.53 nM and 8.19 nM for 5-HT2A and sigma-2, respectively). | [IC 50]
5-HT2A Receptor: 7.53 nM (Ki); Sigma-2 Receptor: 8.19 nM (Ki) | [References]
[1] Davidson M, et al. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry. 2017 Jul 28:appiajp201717010122. DOI:10.1176/appi.ajp.2017.17010122 |
|
|